EGFL7 targeting and/or binding polypeptides and methods for inhibiting angiogenesis

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9789213
APP PUB NO 20150071855A1
SERIAL NO

14388678

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Polypeptides that target and/or bind to EGFL7 or its receptor and thereby reduce EGFL7 pro-angiogenic activity are provided. In this way, the polypeptides are, in an aspect, useful in the treatment of diseases, disorders, or conditions that involve pathological angiogenesis, such as, for example, cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
LONDON HEALTH SCIENCES CENTRE RESEARCH INCLONDON

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Cho, Choi-Fong Guelph, CA 2 1
Lewis, John Edmonton, CA 169 5309
Luyt, Leonard London, CA 5 1

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 17, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 17, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00